NCT05272293View on ClinicalTrials.gov

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

NK cell infusions

Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).

Trial Locations (1)

223053

RECRUITING

Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk

All Listed Sponsors
lead

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

OTHER